Mirtazapine Titration in Acute Inpatient Psychiatric Settings
In an acute inpatient psychiatric unit, increase mirtazapine by increments of the initial dose every 5 to 7 days until therapeutic benefits or significant side effects become apparent. This is the standard approach for antidepressant titration in acute settings.
Specific Titration Protocol
Based on guideline recommendations 1, the following titration schedule should be followed:
- Starting dose: 7.5 mg at bedtime
- Titration interval: Every 5-7 days
- Increment size: 7.5 mg (matching the initial dose)
- Target dose: 30 mg at bedtime (maximum recommended in guidelines)
- Timeline to target: Approximately 2-3 weeks
Practical Titration Schedule
A typical progression would be:
- Days 1-5: 7.5 mg at bedtime
- Days 6-12: 15 mg at bedtime
- Days 13-19: 22.5 mg at bedtime
- Days 20+: 30 mg at bedtime
Important Considerations for Acute Settings
The 5-7 day interval is critical because it allows adequate time to assess both therapeutic response and tolerability before escalating 1. This is particularly important in inpatient settings where patients may have multiple comorbidities and concurrent medications.
When to Accelerate or Modify
While the standard 5-7 day interval applies broadly, certain clinical situations may warrant adjustment:
- Severe insomnia or agitation: The sedating properties of mirtazapine 1 may provide rapid symptomatic relief, potentially justifying staying at lower doses (7.5-15 mg) if sleep improves
- Elderly or medically compromised patients: Consider slower titration (every 7 days minimum) and lower maximum doses 2
- Concurrent CYP3A4 inhibitors: Slower titration warranted due to reduced clearance 2
Therapeutic Trial Duration
A full therapeutic trial requires at least 4 to 8 weeks at an adequate dose 1. This means:
- Titration to target dose: 2-3 weeks
- Maintenance at therapeutic dose: Additional 2-5 weeks minimum
- Total trial duration before considering switch: 4-8 weeks
Dosing Ceiling and Evidence
The guidelines consistently recommend 30 mg at bedtime as the maximum dose 1. This is supported by research showing that flexible titration above minimum licensed doses provides no additional efficacy benefit for mirtazapine 3. The FDA label confirms doses were titrated from 5-35 mg/day in clinical trials, with mean effective doses of 21-32 mg/day 2.
Higher doses (45 mg) are not recommended in acute inpatient settings based on the available guideline evidence, which consistently caps recommendations at 30 mg 1.
Monitoring During Titration
During the titration period, monitor for:
- Therapeutic effects: Improvement in sleep, appetite, and mood typically within 1-2 weeks 4
- Common side effects: Daytime sedation (5.3%), increased appetite/weight gain 1, 4
- Serious adverse effects: Worsening mental status (2.3%), though rare 4
- Suicidality: Particularly in the first 1-2 weeks, as with all antidepressants 5
Special Populations
Obese patients (BMI ≥28): Consider dose reduction by approximately 25-30% due to reduced clearance 6. Start at 7.5 mg but titrate more cautiously to a maximum of 22.5-30 mg.
Patients on paroxetine or fluvoxamine: Significant drug interactions reduce mirtazapine clearance by 27% and 51% respectively 6. Maximum doses should be 22.5-30 mg (paroxetine) or 15 mg (fluvoxamine).
Renal or hepatic impairment: Clearance reduced by 30-50% 2. Use slower titration intervals (every 7 days) and consider lower maximum doses.